Allosteros Therapeutics, Inc.

SUNNYVALE, CA 94089

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $1.76MM
First Award Date 06/15/11
Most Recent Award Date 09/18/17

Key Personnel

Last Name Name Awards Contact
Schulman Howard Schulman 7

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/18/17 - 08/31/18

Type 2 diabetes mellitus has become a worldwide epidemic with significant human and economic burdens. Diabetic patients are particularly at risk of mortality from myocardial infarction and it is therefore important that glucose lowering is achieved by drugs that do not further compromise the heart. Evidence now supports Ca2+/calmodulin-dependent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/11/16 - 12/31/16

? DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cardiac arrhythmia, a condition that predisposes individuals to heart failure and stroke and is a major contributor to cardiovascular mortality. There is an unmet need to treat AF and the underlying electrical and structural changes in heart. There is a long un...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/14/12 - 08/31/13

DESCRIPTION (provided by applicant): Osteosarcoma is the most common primary bone cancer in children and adolescents. A key feature of osteosarcoma is their inherent high growth rates and the increased vasculature to enable rapid growth. Recent data implicate Ca2+/CaM-dependent protein kinase II (CaMKII), a major mediator of Ca2+ signaling, in ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): Ventricular arrhythmias have diverse and complex etiologies that include excessive stimulation of multiple neurohumoral pathological pathways, suggesting that no single upstream blocker will be sufficiently efficacious. Ca[2+]/calmodulin-dependent protein kinase II (CaMKII) is a common downstream mediator of ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): Stroke is a major public health problem, with a US mortality rate that ranks third behind other diseases involving the cardiovascular system and cancer. We propose to pursue neuroprotection in ischemic stroke by targeting a key regulator of Ca2+ homeostasis, Ca2+/CaM-dependent protein kinase II (CaMKII). Inhi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/15/11 - 07/31/13

DESCRIPTION (provided by applicant): Asthma is a major public health problem affecting 25 million American adults and children in the US and over 300 million people globally. It is characterized by reversible airflow obstruction due to bronchial smooth muscle contraction and a diseased epithelial cell phenotype of airway hyper-reactivity (AHR) t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 06/15/11 - 05/31/13

DESCRIPTION (provided by applicant): Heart disease converts to the clinical syndrome of heart failure when the cardiac output is inadequate to meet metabolic requirements. Evidence now supports that pharmacological targeting of Ca2???? dependent protein kinase II (CaMKII), a sensor of dysregulated calcium homeostasis, will inhibit conversion of ...